Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health

Mar.12
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health

Partner Content

Content provided by 【GFN】

 

Registration is now open for the 13th annual Global Forum on Nicotine (GFN26), taking place from Wednesday 3 to Friday 5 June at The Warsaw Presidential Hotel in Warsaw, Poland. Themed Prohibition and public health, this year’s event will examine a deep structural contradiction emerging between science and global public health policy.

 

Despite causing millions of deaths each year, combustible cigarettes remain universally and legally available. Meanwhile, far lower-risk nicotine products – nicotine vapes, pouches, heated tobacco products or Swedish-style snus – are facing blanket or partial bans in many countries. Nicotine does not cause the cancers, cardiovascular disease and respiratory illnesses associated with smoking; these are driven by the toxic byproducts of combustion. Alternative products deliver nicotine without burning tobacco, significantly reducing exposure.

 

 

Regulation, not prohibition

 

 

Effective regulatory frameworks balance the concern over prevention of youth uptake with the huge opportunities to reduce the global burden of death and disease caused by a billion adults who smoke. Yet prohibitive or restrictive policies are endorsed by influential global institutions such as the World Health Organization, justified as being for the ‘protection’ of public health.

 

This directly contradicts years of large-scale epidemiological evidence demonstrating that safer nicotine products reduce smoking rates. In countries where safer products are accessible and affordable, such as Sweden, Norway, the United Kingdom, New Zealand and Japan, cigarette sales have declined much more rapidly, as millions switch away from smoking to safer options.

 

Even as the science-base in support of tobacco harm reduction’s role in public health strengthens, it seems the opposition to safer nicotine products intensifies. GFN26 will critically examine the ways in which prohibition is jeopardising public health goals by entrenching cigarette use, fuelling illicit tobacco and nicotine markets and undermining global efforts to reduce smoking-related disease.

 

The programme will feature keynote addresses, panel discussions and interactive workshops, alongside the return of GFN’s popular Science Lab. Panels and keynote will address:

  • The health, wellbeing and ethical implications of prohibition;
  • The economic impact of prohibition;
  • The unintended consequences of prohibition on illicit markets and organised crime.

 

Jessica Harding, Conference Director, GFN26, said:

 

“Prohibition is increasing at a time when innovation offers unprecedented opportunities to accelerate the end of smoking. Nicotine consumers are paying the price. Unable to access regulated products, millions are forced to choose: either risk using unregulated or illicit nicotine products, or return to deadly tobacco. When cigarettes remain on sale everywhere and safer alternatives are banned or heavily restricted, who is really being protected?”

 

 

An inclusive global platform

 

 

Established in 2014, the Global Forum on Nicotine is the only international conference dedicated to the role of safer nicotine products in helping people move away from smoking.

 

Its open-door, multi-stakeholder approach is unique, welcoming consumers who have switched from smoking, public health professionals, researchers, policymakers, regulators, parliamentarians, manufacturers and media representatives. Many of these groups are either excluded or siloed in other international forums.

 

Speakers and delegates will debate how best to promote evidence-based policy in an environment where harm reduction is frequently portrayed as industry-driven or inherently suspect. By fostering dialogue across sectors, GFN aims to advance practical solutions to reduce smoking-related harm.

 

Affordably priced, GFN26 is a hybrid event. Accommodation at The Warsaw Presidential can be booked at a discounted rate until Monday 4 May. Selected sessions will be streamed live free of charge and simultaneously translated into Spanish and Russian, widening access, and the conference’s broadcast arm, GFN•TV, will again provide live commentary.

 

Opportunities for community participation include the GFN Fives – short, five-minute video contributions published online – and the return of Science Lab, where researchers present emerging findings to an international audience. GFN is open to everyone with an interest in the future of tobacco and nicotine policy – join the event and make your voice heard.

 

In 2026, 2Firsts will continue to serve as an official media partner of GFN, delivering the latest coverage to readers worldwide.

 

GFN 2025
Product | GEEKBAR Adds Two High-Puff Devices to Its Website: Clio Platinum 50K Goes on Sale in the U.S., SOMAX 80K Expands to the Middle East
Product | GEEKBAR Adds Two High-Puff Devices to Its Website: Clio Platinum 50K Goes on Sale in the U.S., SOMAX 80K Expands to the Middle East
Vape brand GEEKBAR has listed two products on its official website—the Geek Bar Clio Platinum 50K and the GEEKBAR SOMAX 80K. The Clio Platinum 50K has already launched across U.S. online retailers, with pricing around US$23.99. The SOMAX 80K is positioned for the Middle East market and had previously been sold in Canada under the name “STLTH X GEEK BAR 80K.”
Feb.09 by 2FIRSTS.ai
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
The EPO Technical Board of Appeal 3.2.02 (T 1319/24) revoked VMR Products LLC’s EP3613453 “VAPORIZER” patent after finding that a 2012 YouTube video of the Innokin iTaste VV (D3) disclosed the claimed electrical contact arrangement. Opponents Nicoventures Trading Ltd (BAT subsidiary) and Philip Morris Products S.A. prevailed.
BATPMI
Feb.17
West Virginia Bill Seeks to Replace Per-mL Vape Liquid Tax With 50% Sales-Price Tax
West Virginia Bill Seeks to Replace Per-mL Vape Liquid Tax With 50% Sales-Price Tax
West Virginia proposes tax rate adjustments on e-cigarette devices and e-liquids, with penalties for late reporting. Effective from July 1, 2026.
Feb.02 by 2FIRSTS.ai
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
Philip Morris International reported full-year 2025 results on February 6, with smoke-free products accounting for 41.5% of adjusted net revenues, up from 38.7% a year earlier. Total net revenues rose 7.3% to $40.65 billion, while shipment volumes increased 1.4%, widening the gap between revenue and volume growth. Cigarette shipments declined as smoke-free volumes rose 12.8%, driven by heated tobacco, oral nicotine and e-vapor products. Results were released alongside a 9:00 a.m. EST webcast.
Feb.06
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24